EGFR突变晚期非小细胞肺癌免疫治疗的研究进展

Research progress of immunotherapy for advanced NSCLC with EGFR mutation

肺癌是全球癌症相关死亡的主要原因。表皮生长因子受体是亚洲肺腺癌患者最常见的突变类型。酪氨酸激酶抑制剂是表皮生长因子受体突变非小细胞肺癌一线首选治疗,但获得性耐药限制了其长期疗效,对于耐药后治疗仍没有有效选择方案。目前,免疫治疗延长了部分患者的生存时间,但在表皮生长因子受体突变非小细胞肺癌中反应较差,介导其疗效不佳的原因仍尚不明确。多种生物标志物的联合评价更能准确预测其免疫治疗疗效并筛选潜在获益人群。联合抗血管生成及新型靶点药物治疗具有免疫增敏作用。本文就表皮生长因子受体突变晚期非小细胞肺癌免疫治疗研究现状、免疫治疗潜在获益人群及免疫联合治疗新策略进行综述。

Lung cancer is the leading cause of cancer-related deaths worldwide.Epidermal growth factor receptor(EGFR)is the most common type of mutation in Asian lung adenocarcinoma patients.Tyrosine kinase inhibitors(TKI)are the first-line treatment of choice for EGFR-mutant non-small cell lung cancer(NSCLC),but acquired drug resistance limits their long-term efficacy.There are still no effective treatment options for advanced NSCLC after drug resistance.Currently,immunotherapy has prolonged the survival time of some NSCLC patients.However,the response is poor in advanced NSCLC with EGFR mutations,and the reasons are still unclear.The combined evaluation of multiple biomarkers can more accurately predict the efficacy of immunotherapy for advanced NSCLC with EGFR mutations and screen potential beneficiaries.The combination of anti-angiogenesis and new target drug therapy has an immune sensitization effect.This article reviews the the current research status of immunotherapy for advanced NSCLC with EGFR mutations,analyzes the potential benefit population of immunotherapy,and discusses new strategies for immunotherapy.